OpGen
OpGen is a biotech company based in Rockville, Maryland, specializing in rapid molecular diagnostics for infectious diseases using its Unyvero platform.
Services
OpGen provides rapid molecular diagnostic products and services tailored to address infectious diseases. Through its advanced diagnostic platforms, the company aims to support healthcare providers by delivering quick and accurate diagnostic results. The primary focus of OpGen's services is on enhancing the diagnosis and management of severe infections, thereby improving patient outcomes.
Products
OpGen offers the Unyvero platform for fast and simple syndromic testing of severe infections. The platform includes various panels, such as the Unyvero LRT panels, which are FDA-cleared for detecting pathogens and antibiotic resistance markers in lower respiratory infections. Another key product, the Unyvero UTI panel, identifies pathogens and antibiotic resistance markers associated with urinary tract infections in less than 5 hours. These products utilize multiplex PCR technology to deliver rapid and detailed results, directly from native specimens.
Technology
The Unyvero system from OpGen leverages multiplex PCR technology to rapidly detect a broad range of microorganisms and antibiotic resistance markers. This advanced technology allows for comprehensive diagnostic outputs in less than 5 hours, facilitating prompt and effective clinical decision-making. Notable among OpGen's offerings is the Unyvero LRT BAL panel, the first and only FDA-cleared panel that includes Pneumocystis jirovecii, enhancing its utility in diagnosing complex infections.
Headquarters
OpGen is headquartered in Rockville, Maryland. This location supports the company's operations, including research and development, production, and administrative functions. The strategic positioning of the headquarters facilitates collaboration with healthcare providers and institutions to advance the development and implementation of their diagnostic products.